H.R.2410 - Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017115th Congress (2017-2018)
|Sponsor:||Rep. Davis, Danny K. [D-IL-7] (Introduced 05/11/2017)|
|Committees:||House - Energy and Commerce | Senate - Health, Education, Labor, and Pensions|
|Committee Reports:||H. Rept. 115-354|
|Latest Action:||Senate - 02/27/2018 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Passed House
Here are the steps for Status of Legislation:
- Passed House
Text: H.R.2410 — 115th Congress (2017-2018)All Information (Except Text)
Text available as:
Referred in Senate (02/27/2018)
Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program and to provide for sickle cell disease research, surveillance, prevention, and treatment.
(a) Short title.—This Act may be cited as the “Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017”.
(b) Table of contents.—The table of contents of this Act is as follows:
Sec. 1. Short title; table of contents.
Sec. 2. Sickle cell disease research.
Sec. 3. Sickle cell disease surveillance.
Sec. 4. Sickle cell disease prevention and treatment.
Sec. 5. Collaboration with community-based entities.
Part P of title III of the Public Health Service Act is amended by inserting after section 399V–6 (42 U.S.C. 280g–17) the following:
“(a) Research.—The Secretary may conduct or support research to expand the understanding of the cause of, and to find a cure for, sickle cell disease.”.
Section 399V–7 of the Public Health Service Act, as added by section 2, is amended by adding at the end the following:
“(A) to conduct surveillance and maintain data on the prevalence and distribution of sickle cell disease and its associated health outcomes, complications, and treatments;
“(i) increasing efforts to improve access to, and receipt of, high-quality sickle cell disease-related health care, including the use of treatments approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of this Act;
“(ii) working with partners to improve health outcomes of people with sickle cell disease over the lifespan by promoting guidelines for sickle cell disease screening, prevention, and treatment, including management of sickle cell disease complications;
“(iii) providing support to community-based organizations and State and local health departments in conducting sickle cell disease education and training activities for patients, communities, and health care providers; and
“(iv) supporting and training State health departments and regional laboratories in comprehensive testing to identify specific forms of sickle cell disease in people of all ages; and
“(i) improving estimates of the national incidence and prevalence of sickle cell disease, including estimates about the specific types of sickle cell disease;
“(ii) identifying health disparities related to sickle cell disease;
“(iii) assessing the utilization of therapies and strategies to prevent complications related to sickle cell disease; and
“(iv) evaluating the impact of genetic, environmental, behavioral, and other risk factors that may affect sickle cell disease health outcomes.
“(2) POPULATION INCLUDED.—The Secretary shall, to the extent practicable, award grants under this subsection to States across the United States so as to include data on the majority of the United States population with sickle cell disease.
“(3) APPLICATION.—To seek a grant under this subsection, a State shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.
“(A) The term ‘Secretary’ means the Secretary of Health and Human Services, acting through the Director of the National Center on Birth Defects and Developmental Disabilities.
“(B) The term ‘State’ includes the 50 States, the District of Columbia, the Commonwealth of Puerto Rico, the United States Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.”.
(1) by striking “Sickle Cell Disease” each place it appears and inserting “sickle cell disease”;
(2) in paragraph (1)(A), by striking “grants to up to 40 eligible entities for each fiscal year in which the program is conducted under this section for the purpose of developing and establishing systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease” and inserting “grants to up to 25 eligible entities for each fiscal year in which the program is conducted under this section for the purpose of developing and establishing systemic mechanisms to improve the prevention and treatment of sickle cell disease in populations with a high density of sickle cell disease patients”;
(A) by striking clause (ii) (relating to priority); and
(B) by striking “Grant award requirements” and all that follows through “The Administrator shall” and inserting “Geographic diversity.—The Administrator shall”;
(4) in paragraph (2), by adding the following new subparagraph at the end:
“(E) To expand, coordinate, and implement transition services for adolescents with sickle cell disease making the transition to adult health care.”; and
(5) in paragraph (6), by striking “$10,000,000 for each of fiscal years 2005 through 2009” and inserting “$4,455,000 for each of fiscal years 2018 through 2022”.
(1) transferred to the Public Health Service Act (42 U.S.C. 201 et seq.); and
(2) inserted at the end of section 399V–7 of such Act, as added and amended by sections 2 and 3 of this Act.
Section 399V–7 of the Public Health Service Act, as amended by section 4, is further amended by adding at the end the following:
“(d) Collaboration with community-Based entities.—To be eligible to receive a grant or other assistance under subsection (b) or (c), an entity must have in effect a collaborative agreement with a community-based organization with 5 or more years of experience in providing services to sickle cell disease patients.”.
Passed the House of Representatives February 26, 2018.
|Attest:||karen l. haas,|